Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 1/Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PURPOSE: This phase I/II trial is to see if bevacizumab works in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00022048

Run by

Stanford University

Starts

2001-08-01

Expected to finish

2004-11-01

Last updated by the study team

2013-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson, Arizona, United States
• Stanford Cancer Center at Stanford University Medical Center — Stanford, California, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.